NHS

Drugs altering gut motility

MHRA Safety update: Metoclopramide is associated with neurological adverse effects. See here for restrictions on dosing and long term use.

MHRA Safety update: Domperidone is associated with an increased risk of cardiac side effects. See here for guidance on dosing, length of treatment and contraindications.

Domperidone is the preferred option for patients with Parkinson's disease.

MHRA Safety Update: Domperidone is contraindicated in patients with underlying cardiac conditions.

MHRA Safety Update: Domperidone for nausea and vomiting - lack of efficacy in children; reminder of contraindications in adults and adolescents

Pack
100 tablet
Pack
200 ml
EMA warning: For high dose and long-term use the benefits of metoclopramide outweigh the risks and a restriction on dosing and duration of treatment is recommended.

Metoclopramide (and to a lesser degree prochlorperazine) is associated with a high risk of dystonias and oculogyric crises particularly in children, young adults and the elderly. It is not licensed for use in people under 20 years of age

Severe reactions to metoclopramide should be treated with procyclidine injection, 5mg to 10mg given intra-muscularly, repeated if necessary after 20 minutes, maximum of 20mg daily. See the Children's BNF for doses in children. 

Pack
84 tablet
Pack
200 ml
Pack
10 ampoule
  • First Line Drugs
  • Second Line Drugs
  • Specialist Initiated Drugs
  • Specialist Only Drugs
  • Mixed Status